Sigma Healthcare (ASX:SIG) raised its fiscal 2025 normalized earnings before interest and tax guidance to a range of AU$64 to AU$70 million, up from the previous guidance of AU$50 to AU$60 million, according to a Friday filing with the Australian bourse.
The increase follows strong performance, particularly from the Chemist Warehouse supply contract that started on July 1, 2024, the filing said.
Statutory net profit after tax for the fiscal year will be "significantly" impacted by non-recurring merger costs, including changes to performance rights, subject to audit completion, the filing added.
The company's shares rose past 5% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.